Integra LifeSciences
IART
281 hedge funds and large institutions have $2.85B invested in Integra LifeSciences in 2023 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 88 increasing their positions, 110 reducing their positions, and 42 closing their positions.
40% more call options, than puts
Call options by funds: $3.46M | Put options by funds: $2.48M
5% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 42
1% more funds holding
Funds holding: 279 → 281 (+2)
4.68% less ownership
Funds ownership: 89.11% → 84.43% (-4.7%)
20% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 110
32% less capital invested
Capital invested by funds: $4.18B → $2.85B (-$1.33B)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
+$44.5M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$19.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$17.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$13.7M |
| 5 |
CC
Clearline Capital
New York
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$80.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$67.7M |
| 3 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$61.1M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$40.8M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
-$27.2M |
IART Hedge Fund Activity: Q2 2023 in Review
281 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2023, worth a combined $2.85B — down 32% from $4.18B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new IART positions and 42 closed out — a net gain of 2 holders — while 88 added to existing stakes and 110 trimmed.
The largest buyer was Madison Avenue Partners, opening a new position worth an estimated $44.5M. The largest seller was Janus Henderson Group, cutting an estimated $80.4M.
- 281 institutional investors held Integra LifeSciences (IART) as of Q2 2023, up from 279 in Q1 2023.
- Funds reported $2.85B of Integra LifeSciences stock for Q2 2023, down 32% quarter-over-quarter.
- 44 funds opened new Integra LifeSciences positions in Q2 2023 and 42 closed out, a net change of +2 holders.
- The largest Integra LifeSciences buyer in Q2 2023 was Madison Avenue Partners, an estimated $44.5M added.
- The largest Integra LifeSciences seller in Q2 2023 was Janus Henderson Group, an estimated $80.4M sold.
Based on aggregated 13F filings for Q2 2023.